Página 66 - v24n1

25. Van Baar HMJ, Van der Vleuten CJM, Van der Kerkhof PCM: Dap-
sone versus topical immunotherapy in alopecia areata. Br J Der-
matol 1995; 132: 270-4.
26. Ellis CN, Brown MF, Voorhees JJ. Sulfasalazine for alopecia
areata. J Am Acad Dermatol 2002; 46: 541-4.
27. Aghael S. An uncontrolled, open label study of sulfasalizine in
severe alopecia areata. Indian J Dermatol Venereol Leprol 2008;
74: 611-3.
28. Talpur R, Vu J, Bassett R et al. Phase I/II randomized bilateral half-
head comparison of topical bexarotene 1% gel for alopecia
areata. J Am Acad Dermatol 2009; 61: 592.e1-9.
29. Khoury EL, Price VH, Abdel-Salam MM, Stern M, Greenspan JS.
Topical minoxidil in alopecia areata: No effect on the perifollicular
lymphoid infiltration. J Invest Dermatol 1992; 99:40-7.
30. Camacho F, Moreno JC, García-Hernandez MJ. Telogen alopecia
from UV rays. Arch Dermatol 1996; 132: 1398-9.
31. Hordinsky M. Sistema nervioso y alopecia areata. Monogr Der-
matol 2010; 23: 255-61.
32. Ehsani A, Toosi S, Seirafi H et al. Capsaicin vs. clobetasol for the
treatment of localized alopecia areata. J Eur Acad Dermatol
Venereol 2009; 23: 1451-3.
33. Hordinsky MK, Ericson ME. Autoimmunity: alopecia areata.
J Investing Dermatol Symp Proc 2004; 9: 73-8.2005; 124:
A102.
34. Hordinsky MK, Ericson ME, Wilcox GL. 180 days of topical cap-
saicin (Zostrix HP:0,075%) to the scalp of two atients with exten-
sive alopecia areata: effect on nerves and neuropeptides.
J Invest Dermatol 2005; 124: A102.
35. Friedli A, Prins C, Chavaz P, Saurat JH. Unsuccessful treatment of
alopecia areata universalis with extracorporeal photopheresis.
Arch Dermatol 2002; 138: 1103-4.
36. Hay IC, Jamieson M, Ormerod AD. Randomized trial of aro-
matherapy. Successful treatment for alopecia areata. Arch Der-
matol 1998; 134: 1349-52.
37. Leslie KS, Shan SN, Darrah C et al. Alopecia universalis treated
with bone morphogenetic protein? Br J Dermatol 2006; 154:
190-1.
38. Adly MA, Assaf HA, Hussein MR. Expresion of bone morpho-
genetic protein-7 in human scalp skin and hair follicles. Br J Der-
matol 2006; 154: 551-4.
39. Heymann WR. Sildenafil for the treatment of Raynaud’s phe-
nomenon. J Am Acad Dermatol 2006; 55: 501-2.
40. Baumhaekel M, Scheffer P, Boehm M. Use of tadalafil in a patient
with secondary Raynaud’s phenomenon not responging to silde-
nafil. Microvas Res 2005; 69: 178-9.
41. Sarifakioglu E, Degim IT, Gorpelioglu C. Determination of the
sildenafil effect on alopecia areata in childhood: An open-pilot
comparison study. J Dermatol Treat 2006; 17: 235-7.
42. Sharquie KE, Al-Obaidi HK. Onion juice (Allium cepa L.), a new topi-
cal treatment for alopecia areata. J Dermatol 2002; 29: 343-6.
43. Willemsen R, Vanderlinden J, Deconinck A, Roseeuw D. Hyp-
notherapeutic management of alopecia areata. J Am Acad Der-
matol 2006; 55: 233-7.
44. Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J. Hypnosis
and alopecia areata: Long-term beneficial effects on psychologi-
cal well-being. Acta Derm Venereol 2011; 91: 35-9.
45. Civas E, Aksoy B, Aksoy HM, Eski M. Hair transplantation for ther-
apy-resistant alopecia areata of the eyebrows: Is it the right
choice? J Dermatol 2010; 37: 823-6.
46. Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM. Lata-
noprost in the treatment of eyelashes alopecia in alopecia areata
universalis. J Eur Acad Dermatol Venereol 2010; 24: 481-5.
volumen 24 • nº 1 • enero-febrero 2011 63